Phio Pharmaceuticals Corp

Phio Pharmaceuticals Corp maintains a strong liquidity position, with a current ratio of 3.47 and cash and equivalents of $4.698 million, which significantly exceeds its total liabilities of $1.523 million. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating a conservative capital structure with no leverage. The price-to-book ratio of 3.45 suggests that the market is valuing the company at a premium to its book value, which may reflect expectations of future growth or innovation. The company is currently unprofitable, with a net loss of $1.846 million and an operating loss of $1.914 million in the latest period. Return on equity (ROE) is negative at -48.93%, and return on assets (ROA) is also negative at -34.86%, indicating that the company is not generating returns on its equity or asset base. The EV/EBITDA ratio is negative at -4.34, which is not uncommon for early-stage biotechnology firms but highlights the lack of current profitability. Phio Pharmaceuticals Corp does not disclose segment or geographic revenue data in the latest financials, so it is not possible to assess revenue concentration or geographic exposure at this time. The company operates as a single business unit focused on biotechnology and medical research, with no disclosed regional breakdown of revenue. The company is in a growth phase, with a market cap of $13.01 million and a mean price target of $14.00 from analysts, which is significantly higher than the current market price of $1.12. However, the company has not provided specific revenue growth projections for the current or next fiscal year, and its operating cash flow is negative at -$3.788 million, indicating that it is not yet generating positive cash from operations. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company has no long-term debt and a strong cash position, which reduces financial risk. There is no indication of dilution pressure in the near term, as shares outstanding for both basic and diluted scenarios are the same at 11.617 million. No recent filings or transcripts have been provided in the input data to assess recent events or strategic developments. The company is currently in a pre-revenue or early-revenue phase, with no disclosed revenue history in the latest financials. The mean analyst recommendation is 2.00, which is a "Buy" rating, but there are no "Strong Buy" ratings, and the high price target is $14.00, suggesting a potential upside of over 1,100% from the current market price. The company's valuation is based on future expectations rather than current financial performance, which is typical for early-stage biotechnology firms.